CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS

Similar documents
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS

Hepatorenal Syndrome

Initial approach to ascites

Hepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover

Beta-blockers in cirrhosis: Cons

The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis

Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

Hepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover

Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis

Elevated Creatinine in a Patient With Cirrhosis

Review article: hepatorenal syndrome definitions and diagnosis

Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis

Hepatorenal syndrome a defined entity with a standard treatment?

Terlipressin: An Asset for Hepatologists!

Therapy Insight: management of hepatorenal syndrome

Management of the Cirrhotic Patient in the ICU

Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality

Abstract. Mohamed Hamdi Saleh 1, Ahmed Hamdy 2, Moataz Elhalag 1. Background: Circulatory dysfunction is known in spontaneous bacterial peritonitis

Patients with cirrhosis frequently develop sepsis because

Hepatorenal syndrome

Hepatorenal Syndrome

JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013

Accepted Manuscript. Acute-On-Chronic Liver Failure, Human Serum Albumin and Immune-Modulation: The Beginning of an Exciting Adventure

Bacterial translocation in cirrhosis

Renal failure is a challenging complication of cirrhosis1,2 and

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS.

HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

Infections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital

Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008

PLASMA COPEPTIN AS A BIOMARKER OF DISEASE PROGRESSION AND PROGNOSIS IN CIRRHOSIS. Journal of Hepatology 2016;65:

L USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO

Original Article. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial

Impact of Serum Sodium with Severity of Complications of Cirrhosis: A Prospective Study in Tertiary Medical Center of Rajasthan

INTRAVENOUS ALBUMIN IN PATIENTS WITH CIRRHOSIS AND SPONTANEOUS BACTERIAL PERITONITIS

BETA-BLOCKERS IN CIRRHOSIS.PRO.

Ascites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites

XV Jornada de Avances en Hepatología Málaga 20 y 21 de Mayo de Barrera intestinal en la cirrosis. Agustín Albillos

Pathophysiology, diagnosis and treatment of ascites in cirrhosis

Hepatorenal Syndrome: Clinical Considerations

Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis

Sign up to receive ATOTW weekly -

RENAL DISEASE IN END STAGE LIVER DISEASE

From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

Prof. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA

Hepatology on the AMU

Renal failure in patients with cirrhosis: a changing paradigma

Hepatorenal syndrome (HRS) is a complication of end stage. Hepatorenal Syndrome. Product Code: SMJ07-10A CME Topic

Management of Cirrhosis and Ascites

The development of hepatorenal syndrome (HRS)

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

TREBALL DE RECERCA. Facultat de Medicina Departament de Medicina Hospital de la Santa Creu i Sant Pau

CIRRHOTIC MANAGEMENT

Acute renal failure is a frequent complication of

Dialyzing challenging patients: Patients with hepato-renal conditions

Cirrhosis Complications

Managing Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis

Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia

Liver-Kidney Crosstalk in Liver and Kidney Diseases

T herapeutic (that is, total) paracentesis is used in patients

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy

Management of Cirrhosis Related Complications

CIRRHOSIS Definition

Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)

Acute kidney injury and hepatorenal syndrome in cirrhosis

Shock, Hemorrhage and Thrombosis

Complications of Cirrhosis

Management of ascites and hepatorenal syndrome

Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1 ( )

High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome

Predictors of hepatorenal syndrome in alcoholic liver cirrhosis

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem

Hyponatremia is a common feature of patients with

Physiological Response to Hypovolemic Shock Dr Khwaja Mohammed Amir MD Assistant Professor(Physiology) Objectives At the end of the session the

How and why to measure renal function in patients with liver disease?

Program Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.

-Cardiogenic: shock state resulting from impairment or failure of myocardium

JMSCR Vol 05 Issue 03 Page March 2017

Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial

ACUTE ON CHRONIC LIVER FAILURE : FROM A TO CLF

Index. Note: Page numbers of article titles are in boldface type.

PACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen

NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW

When Fluids are Not Enough: Inopressor Therapy

Case year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50

Renal dysfunction is a common complication of

Developed for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use

Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome

The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives

HYPEREMIA AND CONGESTION

Developed for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use

Portal hypertension is the main complication of cirrhosis

Review Article Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment

Complication of Portal Hypertension: should the patients in the waiting list be treated differently?

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Transcription:

CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain

CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956

RENAL FAILURE IN CIRRHOSIS SURVIVAL 1.0 Prospective study (2001-2005), n=309) 0.8 Probability 0.6 0.4 0.2 0.0 Median survival = 40 days 0 1 2 3 4 5 6 Months Martín-Llahí M et al., unpublished

CIRCULATORY FUNCTION IN EARLY CIRRHOSIS CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Increased cardiac output MAINTENANCE OF ARTERIAL PRESSURE

CIRCULATORY FUNCTION IN ADVANCED CIRRHOSIS CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output Sodium retention/ascites MAINTENANCE OF ARTERIAL PRESSURE

CIRCULATORY AND RENAL FUNCTION IN ADVANCED CIRRHOSIS CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output Renal vasodilator systems NORMAL KIDNEY FUNCTION

RENAL FAILURE IN CIRRHOSIS MAIN CAUSES 1. Vasodilation-induced renal failure Hepatorenal syndrome (HRS) Bacterial infections 2. Hypovolemia-induced renal failure 3. Drug-induced renal failure 4. Intrinsic renal diseases

PATHOGENESIS OF RENAL FAILURE I. VASODILATION CIRRHOSIS Portal hypertension Disease progression Bacterial infections Bacterial translocation? Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output Renal vasodilator systems HEPATORENAL SYNDROME

PATHOGENESIS OF RENAL FAILURE II. HYPOVOLEMIA CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Bleeding Overdiuresis - Decreased systemic vascular resistance Decreased effective arterial blood volume Bleeding Overdiuresis - Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output Renal vasodilator systems RENAL FAILURE / HYPOVOLEMIC

PATHOGENESIS OF RENAL FAILURE III. DRUG-INDUCED RENAL FAILURE CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output - NSAIDs Renal vasodilator systems RENAL FAILURE

PATHOGENESIS OF RENAL FAILURE IV. INTRINSIC RENAL DISEASES CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output Renal vasodilator systems Other causes RENAL FAILURE Glomerulonephritis

RENAL FAILURE IN CIRRHOSIS MAIN CAUSES 1. Vasodilation-induced renal failure Hepatorenal syndrome (HRS) Bacterial infections 2. Hypovolemia-induced renal failure 3. Nephrotoxicity 4. Intrinsic renal diseases

CIRCULATORY AND RENAL FUNCTION IN HEPATORENAL SYNDROME CIRRHOSIS Portal hypertension Splanchnic arterial vasodilation Decreased effective arterial blood volume Vasoconstrictor systems Cerebral vasoconstriction Renal vasoconstriction Brachial/femoral vasoconstriction Maintenance of effective arterial blood volume HEPATORENAL SYNDROME

CIRCULATORY AND RENAL FUNCTION IN HEPATORENAL SYNDROME CIRRHOSIS Portal hypertension Vasoconstrictors Splanchnic arterial vasodilation Decreased effective arterial blood volume Vasoconstrictor systems Cerebral vasoconstriction Renal vasoconstriction Brachial/femoral vasoconstriction Maintenance of effective arterial blood volume HEPATORENAL SYNDROME

CIRCULATORY AND RENAL FUNCTION IN HEPATORENAL SYNDROME CIRRHOSIS Portal hypertension Vasoconstrictors Splanchnic arterial vasodilation Albumin Decreased effective arterial blood volume Vasoconstrictor systems Cerebral vasoconstriction Renal vasoconstriction Brachial/femoral vasoconstriction Maintenance of effective arterial blood volume HEPATORENAL SYNDROME

Drugs used HEPATORENAL SYNDROME PHARMACOLOGICAL TREATMENT Terlipressin, Norepinephrine, Midodrine Key findings Improves renal function in 50-75% of patients Response to therapy is associated with improved survival Recurrence not constant. Retreatment effective Unknown issues Overall effect on survival No comparative studies between different drugs Beneficial effect of associated albumin likely but not proved

HEPATORENAL SYNDROME TREATMENT WITH TERLIPRESSIN AND ALBUMIN Survival and response to therapy Recurrence 1.0 1.0 Probability 0.8 0.6 0.4 Responders p<0.03 Probability 0.8 0.6 0.4 0.2 Non responders 0.2 0.0 0 30 60 90 0.0 0 30 60 90 Days Days Martín-Llahí M et al., unpublished

RENAL FAILURE IN CIRRHOSIS MAIN CAUSES 1. Vasodilation-induced renal failure Hepatorenal syndrome (HRS) Bacterial infections 2. Hypovolemia-induced renal failure 3. Nephrotoxicity 4. Intrinsic renal diseases

PATHOGENESIS OF RENAL FAILURE IN BACTERIAL INFECTIONS CIRRHOSIS Bacterial infection Increased cytokine production Splanchnic arterial vasodilation Decreased systemic vascular resistance Decreased effective arterial blood volume Increased blood/plasma volume Activation of vasoconstrictor systems Increased cardiac output RENAL FAILURE Renal vasodilator systems

Incidence BACTERIAL INFECTIONS AND RENAL FAILURE 20-30% of patients with spontaneous bacterial peritonitis or sepsis in the absence of septic shock 40% of cases of renal failure in cirrhosis Key findings Reversible or non-reversible May progress despite infection resolution Associated with poor outcome

RENAL FAILURE IN CIRRHOSIS SURVIVAL 1.0 0.8 Bacterial infections Hepatorenal syndrome Probability 0.6 0.4 0.2 0.0 p=ns 0 1 2 3 Months Martín-Llahí M et al., unpublished

SPONTANEOUS BACTERIAL PERITONITIS CIRCULATORY DYSFUNCTION AND RENAL FAILURE 25 * Plasma renin activity (ng/ml.h) 20 15 10 5 * p<0.05 * * * 0 0 3 6 9 Days No renal failure Renal failure Sort et al., N Engl J Med 1999

PATHOGENESIS OF RENAL FAILURE IN BACTERIAL INFECTIONS IN CIRRHOSIS CIRRHOSIS Portal hypertension Bacterial translocation to lymph nodes Bacterial infection (SBP, sepsis) Increased cytokine production Impairment of circulatory function (arterial vasodilation) Impairment of cardiac function ALBUMIN Reduction of effective arterial blood volume Activation of vasoconstrictor systems RENAL FAILURE

SPONTANEOUS BACTERIAL PERITONITIS EFFECTS OF ALBUMIN 30 Renal failure (%) Mortality (%) 30 20 p=0.02 20 p=0.01 10 10 0 Cefotaxime Cefotaxime + albumin 0 Cefotaxime Cefotaxime + albumin Sort et al., N Engl J Med 1999

BACTERIAL TRANSLOCATION IN CIRRHOSIS Intestinal Bacterial Overgrowth Dysmotility Delayed transit time Aerobic bacteria Anaerobic bacteria Enterocytes Intestinal Permeability Mucosal Hypoxia, Acidosis ATP depletion, NO, LPS, TNF Impaired Immunity Impaired chemotaxis, migration, phagocytic function, complement deficiency, etc. Lamina propria Garcia-Tsao et al., Best P Res Clin Gastroenterol 2004

BACTERIAL TRANSLOCATION AND EFFECTS OF NORFLOXACIN Experimental cirrhosis (%) Human cirrhosis (%) 70 69% 70 60 60 50 42% 50 40 30 31% 40 30 31% 20 20 10 0 0% Control rats Cirrhosis with ascites Placebo Norfloxacin 10 0 9% Controls 6% Child A/B Child C 9% Norfloxacin Cirrhosis with ascites and hemorrhagic shock Patients with cirrhosis Llovet et al., Hepatology 1996 Cirera et al., J Hepatol 2001

POSSIBLE CONSEQUENCES OF BACTERIAL TRANSLOCATION IN CIRRHOSIS - Infections due to bacteria from intestinal origin (spontaneous bacterial peritonitis, sepsis) - Increased cytokine production - Increased nitric oxide / carbon monoxide production - Impairment of circulatory / renal function

POSSIBLE CONSEQUENCES OF BACTERIAL TRANSLOCATION IN CIRRHOSIS - Infections due to bacteria from intestinal origin (spontaneous bacterial peritonitis, sepsis) - Increased cytokine production - Increased nitric oxide / carbon monoxide production - Impairment of circulatory / renal function

BACTERIAL TRANSLOCATION CYTOKINE AND NITRIC OXIDE PRODUCTION TNFα in lymph nodes (pg/ml) TNFα in plasma (pg/ml) Nitric oxide in plasma (10-3 M) * 140 50 * 40 120 p<0.05 * 40 p<0.05 30 p<0.05 * 100 30 20 80 20 60 10 10 40 0 0 Control LC, BT- LC, BT+ Wiest et al., J Clin Invest 1999

CIRCULATORY FUNCTION IN CIRRHOSIS EFFECT OF SELECTIVE INTESTINAL DECONTAMINATION Mean arterial pressure (mmhg) Systemic vascular resistance (units) Rasaratnam et al., Ann Intern Med 2003

BACTERIAL TRANSLOCATION AND CIRCULATORY / RENAL FUNCTION CIRRHOSIS SELECTIVE INTESTINAL DECONTAMINATION Portal hypertension Bacterial translocation to lymph nodes Increased cytokine production Impairment of circulatory function (arterial vasodilation) Reduction of effective arterial blood volume Activation of vasoconstrictor systems HEPATORENAL SYNDROME

SELECTIVE DECONTAMINATION IN CIRRHOSIS EFFECT ON RENAL FUNCTION AND SURVIVAL Patients with advanced liver falure and low protein ascites Hepatorenal syndrome Survival 1.0 0.8 p=0.02 1.0 0.8 Norfloxacin Probability 0.6 0.4 0.2 0.0 Placebo Norfloxacin 0 100 200 300 400 Probability 0.6 0.4 0.2 0.0 Placebo p=0.05 0 100 200 300 400 Days Days Fernández et al., unpublished

ACKNOWLEDGEMENTS Family Mentors Collaborators Núria Anna Núria Marta V. Arroyo J. Rodés RW. Schrier C. Alessandria R. Bataller S. Badalamenti I. Bucknan ME. Baccaro B. Calahorra A. Cárdenas R. Cela D. De las Heras G. Fernández-Esparrach A. Ginès M. Guevara W. Jiménez J. Llach M. Martín-Llahí R. Ortega O. Ozdogan MN. Pépin R. Planas T. Restuccia J. Saló P. Sort C. Terra Ll. Titó A. Torre J. Uriz

Let every student have full recognition for his work. Never hide the work of others under your own name. Should your assistant make an important observation, let him publish it. Through your students and your disciples will come your greatest honor. Sir William Osler (1849-1919)